KPTI KPTI - Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer - Click For Release
KPTI KPTI - Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer - Click For Release
Story updates
08:12:21 PM UTC
SquawkNews
KPTI Karyopharm announces topline results from phase 3 xport-ec-042 trial in endometrial cancer Karyopharm Therapeutics - phase 3 xport-ec-042 trial does not meet primary endpoint - No new safety signals observed for selinexor in phase 3 trial - To reduce planned investment in endometrial cancer program
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.